Gingival hyperplasia associated with the administration of amlodipine to dogs with degenerative valvular disease (2004-2008)

Journal of Veterinary Internal Medicine

Volumn 23, Issue 1, 2009, Pages 39-42

  Thomason, J D ^a,b   Fallaw, T L ^a   Carmichael, K P ^a   Radlinsky, M A ^a   Calvert, C A ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

Calcium channel blockers; Dentistry; Mitral regurgitation; Systemic hypertension

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; SPIRONOLACTONE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CHEMICALLY INDUCED DISORDER; DOG; DOG DISEASE; FEMALE; GINGIVA HYPERPLASIA; MALE; RETROSPECTIVE STUDY; VALVULAR HEART DISEASE;

AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CALCIUM CHANNEL BLOCKERS; DIURETICS; DOG DISEASES; DOGS; ENALAPRIL; FEMALE; GINGIVAL HYPERPLASIA; HEART VALVE DISEASES; MALE; RETROSPECTIVE STUDIES; SPIRONOLACTONE;

ANIMALIA; CANIS FAMILIARIS;

EID: 61349127884     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2008.0212.x     Document Type: Article

References (24)

1. Abernethy DR. Calcium-antagonist drugs. N Engl J Med 1999;341:1447-1455.
2. Stopher DA, Beresford AP, Macrae PV, et al. The metabolism and pharmacokinetics of amlodipine in humans and animals. J Cardiovasc Pharmacol 1988;7:S55-S59.
3. TOMH Study. Treatment of mild hypertension study (TOMH). Final results. JAMA 1993;220:713-724.
4. ALLHAT Collaborative Research Group. Major outcomes of major high-risk hypertensive patients randomized to angiotensin- converting enzyme inhibitor or calcium channel blocker vs diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-2997.
5. Turnbull F. Blood pressure lowering treatment trialists' collaboration. Effects of different blood-pressure lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomized trials. Lancet 2003;362:1527-1535.
6. Ellis SJ, Seymour RA, Steele JG, et al. Prevalence of gingival overgrowth induced by calcium channel blockers: A community- based study. J Periodontol 1999;70:63-67.
7. The BENCH (BENazepril in Canine Heart disease) Study Group. The effect of benazepril on survival times and clinical signs in dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial. J Vet Cardiol 1999;1:7-18.
8. Ettinger SJ, Benitz AM, Ericsson GF, et al. Effects of enal-april maleate on survival of dogs with naturally occurring acquired heart failure. J Am Vet Med Assoc 1998;213:1573-1577.
9. Kitagawa H, Wakamiya H, Ito K, et al. Efficacy of monther-apy with benazepril, an angiotensin converting enzyme inhibitor, in dogs with naturally acquired chronic mitral insufficiency. J Vet Med Sci 1997;59:513-520.
10. The COVE Study Group. Controlled clinical evaluation of enalapril in dogs with heart failure: Results of the cooperative veterinary enalapril study group. J Vet Intern Med 1995;9:243-252.
11. Kvart C, Haggstrom J, Pedersen HD, et al. Efficacy of enal-april for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation. J Vet In Med 2002;16:80-88.
12. Atkins CE, Keene BW, Brown WA, et al. Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency. J Vet Med Assoc 2007;231:1061-1069.
13. RALES Study. For the randomized aldactone evaluation study investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.
14. Atkins CE, Rausch WP, Gardner SY, et al. The effect of am-lodipine and the combination of amlodipine and enalapril on the renin-angiotensin-aldosterone system in the dog. J Vet Pharmacol Ther 2007;30:394-400.
15. Jorgensen MG. Prevalence of amlodipine-related gingival hyperplasia. J Periodontal 1997;68:676-678.
16. Ellis SJ, Seymour RA, Thomason JM, et al. Gingival sequestration of amlodipine and amlodipine-induced gingival overgrowth. Lancet 1993;341:1102-1103.
17. Beresford AP, Macrae PV, Stopher DA. Metabolism of amlodipine in the rat and the dog: A species difference. Xenobiotica 1988;18:169-182.
18. Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol 1996;23:165-175.
19. Barclay S, Thomason JM, Idle JR, et al. The incidence and severity of nifedipine-induced gingival overgrowth. J Clin Perio-dontol 1992;19:311-314.
20. Steel RM, Schuna AA, Schreiber RT. Calcium antagonist- induced gingival hyperplasia. Ann Intern Med 1994;120:663-664.
21. Bullon P, Macheca G, Martinez-Sahuquillo A, et al. Clinical assessment of gingival hyperplasia in patients treated with nifedipine. J Clin Periodontol 1994;21:256-259.
22. Harel-Raviv M, Eckler M, Lalani K, et al. Nifedipine-induced gingival hyperplasia. A comprehensive review and analysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;79:715-722.
23. Nery EB, Edson RB, Lee KK, et al. Prevalence of nifedipine-induced gingival hyperplasia. J Periodontol 1995;66:572-578.
24. Seymour RA, Ellis JS, Thomason, et al. Amlodipine-induced gingival overgrowth. J Clin Periodontol 1994;21:281-283.